

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

INSIDE INFORMATION
THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF
CHINA GRANTS NEW DRUG APPROVAL TO MENHYCIA

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

References are made to the announcements of the Company dated July 8, 2019, November 22, 2019, December 16, 2019 and July 26, 2020, respectively, in relation to, among other things, the progress of new drug application and preparation for commercialization of the Company’s Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (“**MCV4**”, trade name: Menhycia).

The Company is pleased to announce that, the National Medical Products Administration of China has granted new drug approval to the Company’s MCV4. Menhycia is the first vaccine of this kind being approved in China.

MCV4 is developed and manufactured by the Company for the prevention of epidemic cerebrospinal meningitis associated with *N. meningitides* (Lta) infection by groups A, C, Y and W135. It is applicable to children aged from 3 months to 3 years old (47 months). The studies show that MCV4 is safe and well-tolerated, and have good immunogenicity in all age groups in clinical trials.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, December 29, 2021

As of the date of this announcement, the board of directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.